Cargando...
Silencing of ECHDC1 inhibits growth of gemcitabine-resistant bladder cancer cells
Combined gemcitabine and cisplatin (GC) treatment is a first line chemotherapy for bladder cancer. However, acquired resistance to GC has been a major problem. To address the mechanism of gemcitabine resistance, and to identify potential biomarkers or target proteins for its therapy, we aimed to ide...
Gardado en:
| Publicado en: | Oncol Lett |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
D.A. Spandidos
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5769416/ https://ncbi.nlm.nih.gov/pubmed/29391886 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.7269 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|